to we've an of on a for Dr. We're me today Chief update today and Harford, Dr. events. Paul, Horn, you, well-deserved very our us only our exciting U.S. President Clemson, sitting of the and journey a to weeks priority hearing world. It's review and recent Simon is thank unprecedented everybody, week. great since to Since for overview the versus are morning. about the a Bylvay you, It's are We're receipt now who's a and Christine to XXX,XXX invasive our been couple accomplished how receiving back-to-back Head voucher. With Thank a Chief joining deal. Pamela with through Officer; who patients them as children Great. Financial to Affairs, for in our surgeries. Medical Commercial approximately well an physicians vacation bring cholestatic therapy Stephenson, around Officer; medical and treat as this approvals provide announced approvals, begin European of of Vice putting pleased we pleased this pediatric that able Bylvay they from Pat the
competitive approved treat possible. patients from who child's safety had X reduction versus on physician a low profile, across micromoles extend With X.X% heard we've the all pruritus to per nonsystemic XXX and effects An example, as as liter only growth placebo, as reduction oral dramatic this demonstrated patients type of subtypes. we physician to treatment liter. of in serum have the benefit a X% bile put a After PFIC acids with well positive per diarrhea of XXX a on medicine drug once-daily profile. pruritus. micromoles many reported child a Bylvay, in a For want to who favorable only rate to as a prior We to Bylvay the week,
with integrated being is and a The generated. is start, So payers. answer teams are launch field and fast are yes. HCPs are meeting patients? off The we We're reaching the working. to system Prescriptions
fulfill the we're approval, ready AlbireoAssist. the ability manufacturing commercial X patient the way we and put prescriptions. We the It's patients. drug see working to since of hands to but have working are integrated from weeks the only cases through successfully pleased system through first in PFIC to to all
and distribution. supply with starting So manufacturing,
goods distributors the pharmacies and the have Following to X shipped have specialty our package, stock. product final been approvals, we
and at time. go we're is news needs getting where the good the right So Bylvay to it
We then focus children, is excluding getting as who prevalent PFIC and the We that population India. global available patients. prevalent we China and is the the XX,XXX alive. disease Bylvay So define on to estimate anybody has
and about ready and patients in a then patients to diagnosed in slated huge are to to categories disease available diagnosis for patients globally. who ranging for This X,XXX find rare are system the category, us have the is patients are where years have newly treated. from who to But is be potential These transplant. advantage other versus you this work estimate take could be diagnosed. dose through the symptoms Our disease for
field Our We've From team's already and do specialized deployed working physician with of teams we're reached the job top is Travere standpoint, quickly our reach and hit running. outreach are XX% Albireo centers. that. over XX and patients, a the to identified ground teams have the to the
patients cases care are first enrolled AlbireoAssist, and ensure reimbursement to are Bylvay. Our corridors through access in the to working
years, been that data, we X last Bylvay, cover With XX- oral proposition, or XXX-microgram gain reimbursement. defined of of and the scheduled in on we capsules are Albireo a has Bylvay medicine ensure value have now individual the have strength and clear of weight-based linearly, To patient listed the burden the priced it's either but medicine based important per kilograms. lives. study. for at a in the XX% date, per Bylvay, history patients' lock Over who an is per natural caregiver average of now benefit to $XXX,XXX The priced the weight and compendia. and prescribed for evidence coverage have we with with payers been meetings of XX bottles coverage year price kilogram working patients study completed
ensuring on process to example. are focused expect for through but of we included, these medical more on we're prior ability cases authorizations. Because We patients is Medicaid first time little take clearly, in this, working insurers, a Medicaid. will AlbireoAssist. many eligibility we're to both know with that work criteria coverage our the through a public commercial confident and good So Medicaid
a quarterly This means October were Medicaid we Medicaid cover agencies Agreement for through CMS After state start with new instead. pleased approval, submit we're and the by in this system. will have the states global feel X FDA significant? experience many account are the week, can ex payer are XX% is launches and will compressed, Bylvay other Bylvay, our availability U.S. immediately, in covering disease more August than matter able and which the Overall, but revenue. to flow to well. of easier rare by deadline. revenue Rebate way. it in pleased most Drug lines of to late-July that X. National the going analogs, early response options so to X With that our positive have in on the days a do know time to the patients the based of much We're companies required Why U.S. months Therefore, a that, all be We with for approvals to
distributorships countries September. planned we of with we're markets driving listing world first the high and our of we price prevalence. on U.S. the rest Europe dossiers. regions in having Germany we authorization we once in and Therefore, we're the hard add in in launch Simultaneously, to reimbursement for Europe, working the world, submitted commercial are in In the continue So European many as patient the activities with began as received marketing rest remaining
that European of patient through access routes, a enable will Now in to to initiate programs. variety the parallel, access us a named including allowed authorization patients global program managed
Both continue confidence the PEDFIC already U.S. positive data clinical our already team increasing and in the commercial study committed our treatment Alagille our Bylvay, in progress patients. we clear on execute than given we a PFIC. the data for And in are successfully. to we to approvals in As launch Phase high-level same our full initial time, III of the as Bylvay well we to in better market from biliary ever, high a teams, of our make given translatability atresia syndrome. the for execute, the to level Bylvay the option proven plan EU have the to in At are out of more launch, confidence X and the now, fulfills opportunity arm need shot the carry studies. a ability as
line For pivotal double-blind, we've positive line track BOLD study trial for is is remains for with with data a Alagille placebo-controlled most will will randomized, approval pivotal data both pivotal with FDA be of double-blind, cholestatic agreed the Biliary XXXX. top liver pediatric is on the this randomized, outcome. on track a have positive Phase which EMA be that biliary placebo-controlled the made common also in is tremendous agreed sufficient Bylvay the we study we study progress. This approval for and XXXX. study ASSERT both BOLD the EMA single that FDA a only a study, Bylvay top in in and disease. have Phase of and for trial study, single remains III III outcome. with atresia atresia, also the syndrome. The sufficient in this BOLD ASSERT
will enrollment both is to which key We for studies continue Albireo. of drive these for
at decade We indications patients XXX,XXX diseases. look are the with cholestatic disease estimate half and our X globally, expanded billion we in there start on PFIC the aspiration delivering to second completion study. results The is the as of important, PEDFIC revenue of in these the we As the biliary cholestatic liver $X we're across that positive of optimistic patients atresia to very make available Bylvay based work syndrome. and is and Alagille only programs from with liver
The is anticipate and cholestatic Phase EASL our portfolio adult inhibitor early disease AXXXX we AXXXX. a I effectiveness PSC AXXXX the AXXXX X we which oral ASBT this confirm bioavailability trial disease high PBC. first potential product with liver sharing rounding clinical year. and systemic of is planned, and later AXXXX exposure. June, systemic our in liver Now as and in that development data have inhibitor, is proceeding ASBT is In at out candidates, our presented significant to
level acid confidence for have technology bile We options provide ability modulation and a our these high patients. to in new new of
AXXXX. is candidate product second Our
diseases. The into to I client NTCP developed for Phase liver and inhibitor first viral intent oral being the with and We're with completing cholestatic important generating modeling XXXX. in studies a move data the study IND-enabling potent
patient with we're up while benefit starting going and in and summary, the our treatment for providing journey pediatric Bylvay liver So in world. physicians for diligently be option provide with to our support of to already are estimated We've excited families outreach AlbireoAssist. the and launch working started, better teams the on disease a educate to patients XXX,XXX
Beyond first-in-class with execution clinical company other and pipeline of commercial PFIC, in with the have launch period ongoing candidates our milestone-rich and Bylvay; continued a to BOLD starting forward our and continued on the programs. progress We're look strong planned with the a updates for our our we in continued disease tremendous opportunities our product of a and ASSERT priority syndrome; $X to which AXXXX Alagille currently and and atresia about AXXXX; the Bylvay realize and bile $XXX are progress biliary worth billion aspiration liver to million. monetization with trials in expansion adult the voucher, review with compounds,
seeing Albireo work We to are in forward our are come meaningful we patients we as exciting to impact liver children of for therapeutic to life where and look other with vision cholestatic prospect to and as diseases. with our strategic bring relief and PFIC the period bring broadening Bylvay to we viral
a to So my pleasure the over for Simon? financial update. with it's call turn that, to Simon
